Get the Daily Brief
Latest Biotech News
Breakthrough Allogeneic CAR T Cell Therapy for Multiple Sclerosis
The University of Nebraska’s Fred & Pamela Buffett Cancer Center pioneered the first administration of an allogeneic CD19-directed CAR T-cell therapy, azercabtagene zapreleucel (azer-cel), to a...
SARS-CoV-2 Host Factor Identification Opens New Drug Targets
Scripps Research scientists performed a genome-wide siRNA screen to pinpoint essential human host proteins exploited by SARS-CoV-2 during its replication cycle. The study identified over 30 host...
Novartis Deepens Cardiovascular RNA Therapeutics with Argo Biopharma Deal
Novartis signed a multi-asset licensing and option agreement with Argo Biopharma worth up to $5.2 billion, gaining rights to siRNA candidates targeting severe hypertriglyceridemia and mixed...
Breakthroughs in Single-Cell Analysis and Spatial Transcriptomics
Cutting-edge bioinformatics advances herald new capabilities in understanding complex cellular systems. The GNODEVAE graph-based ODE-VAE method was introduced to enhance clustering accuracy in...
Pioneering Gene Therapy and Immunotherapy in Cancer and Skin Disorders
Recent research milestones include the landmark FDA approval of beremagene geperpavec (B-VEC), the first topical gene therapy for the rare skin disease epidermolysis bullosa, offering profound...
New Advances in Targeted Lung Cancer Therapies: Osimertinib Combinations and Bispecific ADCs
Recent clinical trials and research have demonstrated promising advancements in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). The FLAURA2 trial revealed improved overall...
Geographic Variability Challenges Summit Therapeutics’ Lung Cancer Drug Approval Plans
Summit Therapeutics faces regulatory hurdles arising from divergent clinical trial outcomes with ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in NSCLC treatment. Phase III data...
Novel NSCLC Treatments and Immune Checkpoint Inhibitors Show Quality of Life Preservation
Emerging treatments in early and advanced NSCLC demonstrate promising efficacy without compromising patients’ quality of life. The Phase 3 CheckMate 77T trial revealed that perioperative...
AI Validation and Bioinformatics Advances in Precision Medicine and Cancer Risk Prediction
Artificial intelligence continues to forge new paths in healthcare, with recent validations enhancing its clinical utility. The Sybil AI lung cancer risk model demonstrated high accuracy in...
FDA Expands Transparency and Regulatory Oversight in Drug Approval Processes
The U.S. Food and Drug Administration is intensifying efforts toward transparency and regulatory modernization. The agency is now releasing complete response letters (CRLs) to drug sponsors...
Groundbreaking Cell and Gene Therapy Innovations Target Neurological and Rare Diseases
Cutting-edge cell and gene therapy developments are reshaping treatment landscapes for complex and rare conditions. The University of Nebraska pioneered the world’s first allogeneic CAR T-cell...
Big Pharma Deal-Making and Financing Drive Biotech Innovation and Pipelines
The biotech sector remains buoyed by substantial financial investments and strategic licensing agreements. Novartis expanded its RNA interference portfolio through a $160 million upfront...
Emerging Cancer Therapeutics: ADCs, Oncolytic Viruses, and Immunotherapy Targets
Innovative therapeutic modalities in oncology are advancing rapidly. BioNTech and DualityBio reported a Phase 3 interim breast cancer ADC success, demonstrating improved progression-free survival...
Microbiome and Viral Pathogen Research Reveal New Therapeutic Targets and Disease Mechanisms
Recent studies have uncovered critical relationships between host microbiomes, viral infections, and disease. Scripps Research identified dozens of human host proteins essential for SARS-CoV-2...
New Lung Cancer Therapies Show Promise in EGFR-Mutated NSCLC
Recent clinical trials reveal significant advancements in therapies targeting non-small cell lung cancer (NSCLC) patients with EGFR mutations. The ACROSS 2 Phase III trial demonstrated that...
Summit Therapeutics Faces Regional Efficacy Challenges with Ivonescimab
Summit Therapeutics reported mixed Phase III data for ivonescimab combined with chemotherapy in lung cancer across geographic regions. The drug demonstrated a 45% reduction in tumor progression...
FDA Enhances Transparency with Real-Time Release of Drug Rejection Letters
The U.S. Food and Drug Administration has committed to publishing complete response letters (CRLs) shortly after issuance to drug sponsors, representing a major policy shift toward transparency....
Innovations in Cancer Therapy: Bispecific ADCs and Oncolytic Virus Synergies
Recent oncology breakthroughs include bispecific antibody-drug conjugates and novel oncolytic virus-immunotherapy combinations poised to expand treatment horizons. Radiance Biopharma secured a...
Artificial Intelligence Advances Precision and Predictive Tools in Biotech
Artificial intelligence continues to reshape biotech research and clinical applications, with breakthroughs including the development of AI models validated in diverse populations and novel...
Allogeneic CAR T Therapy Breakthroughs in Autoimmune and Cancer Treatment
Innovations in chimeric antigen receptor T cell (CAR T) therapies demonstrate expanding applications beyond oncology. The first allogeneic CD19-directed CAR T-cell treatment was administered to a...